• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

GC Group's 3 generations making their presence felt...'uncle-nephew' is gone, 'cousin management' is coming

김나영 기자

steaming@fntimes.com

기사입력 : 2024-12-23 17:18

Heo Il-seop, GC Group Chairman's Eldest Son, Promoted to CFO after 8 Years
Signs of Change in Management System from Uncle and Nephew to Owner's Third-Generation Cousin
"It Seems Like 'Beautiful Management' Will Continue Even Under Cousin Management System"

GC Green Cross office building./Photo=GC Green Cross

GC Green Cross office building./Photo=GC Green Cross

[Korea Financial Times, Kim Nayoung] GC Green Cross Group (GC Group) is in the mood to switch from the 'uncle-nephew' system that has been in place for about 10 years to 'cousin management'.

According to the pharmaceutical industry on the 23rd, the Green Cross Group is recently starting the 'owner's third generation' management in earnest through the regular executive personnel reshuffle in 2025. This is because GC Group Chairman Heo Il-seop's eldest son, Heo Jin-seong, in charge of GC Strategy 1, has been promoted to the head of the business management headquarters (executive director). He was appointed as the chief financial officer (CFO) of the holding company, GC Green Cross Holdings, changing his position from strategy to finance. It has been eight years since a member of the GC Group's owner family was promoted.

Executive director, Heo Jin-seong will be responsible for the overall management of the group, including not only accounting, but also investment, financing, and M&A.

There are voices in the industry saying that this personnel change is the beginning for GC Group's management succession. The current GC Group is jointly managed by an uncle and nephew. After the passing of GC Group Chairman Heo Young-seop in 2009, GC Holdings has been led by his younger brother, Chairman Heo Il-seop.

In 2015, the second son of former Chairman Heo Young-seop, Heo Eun-cheol, became the CEO of GC Green Cross, a key affiliate, and the uncle-nephew joint management began. Then, in 2017, former Chairman Heo’s third son, Heo Yong-jun, also entered the board of directors of Green Cross Holdings and became co-CEO with his uncle, Chairman Heo Il-seop.

There had been many speculations that if Chairman Heo Il-seop stepped down from management, the management of the brothers would begin, but the emergence of new headquarters director Heo Jin-seong has given strength to the possibility of cousin management. In particular, as the head of the management headquarters, which Executive Director Heo Jin-seong took on, was a key position that President Heo Yong-jun held just before he became CEO, Executive Director Heo Jin-seong could succeed Chairman Heo Il-seop in the future. Chairman Heo Il-seop was born in 1954, so it would not be strange for him to be considering succession.

In addition, Chairman Huh Il-seop's second son, Huh Jin-hoon, is also working as the head of the Aliglo team at the Global Business Headquarters at GC Green cross. He is in charge of the global business of 'Aliglo', an immunoglobulin product that has emerged as GC Green Cross's next-generation growth engine. However, he was born in 1991, so he is different in job title from other third-generation members born in the 1970s and 1980s.

Looking at the shareholding structure, all four third-generation owners have a strong presence. Chairman Huh Il-seop is the largest shareholder of Green Cross Holdings, holding 12.20%. He is followed by ▲President Huh Yong-joon with 2.91%, ▲President Huh Eun-cheol with 2.63%, ▲Executive Director Huh Jin-seong with 0.77%, and ▲ Huh Jin-hoon with 0.72%. Although Chairman He's eldest and youngest sons have lower stakes than their cousins, but that could change depending on how Mr. He handles his stake in the future.

Some in the market are speculating that the cousins may compete for shares in the future. However, the prevailing opinion is that GC Group will continue to show the same stability it has shown in its uncle-nephew management for more than a decade.

An industry insider explained, “The pharmaceutical industry calls GC Group ‘beautiful management’,” and “The pharmaceutical industry is an industry dominated by owner management, so there is a certain amount of management dispute, but GC Group, on the contrary, is showing balanced joint management.” He added, “Even if the system changes to cousin management, it will show the same beautiful management as it does now.”

Kim Nayoung, Korea Finacial Times (steaming@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

기자의 기사 더보기 전체보기

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 LG Chem Petrochemicals Face Losses Despite NCC Restart; Advanced Materials Recovering Petrochemicals is once again LG Chem’s main concern. While earnings at its battery subsidiary and advanced materials business are improving, its petrochemicals division, which returned to profit in the first half, is expected to slip back into the red in the second half. The No. 2 naphtha cracking center (NCC) plant in Yeosu, idled for about six months, has resumed operations. But a profit recovery looks difficult as the negative inventory lag effect from falling feedstock prices and higher logistics costs weigh on results.According to financial data provider FnGuide on the 22th, the consensu 2 Hanwha Systems Raises KRW 3.4 Trillion as It Winds Down ‘Bridge’ Role in Hanwha Ocean Deal Hanwha Systems is raising KRW 3.4 trillion through a price return swap (PRS) on its Hanwha Ocean shares and the sale of its stake in the Philly shipyard in the United States. Both assets came out of Hanwha Systems’ efforts to back the Hanwha Group’s push to strengthen its shipbuilding business. The company is now expected to end its “bridge” role and concentrate on strengthening its core business through capital reallocation.According to the investment banking (IB) industry on Oct. 20, Hanwha Systems recently decided to transfer all 22,169,660 of its Hanwha Ocean common shares to Kiwoom Se 3 Hanmi Pharm Hit by Shareholder Feud, Rights Return; Next Obesity Drug Key to Rebound Hanmi Pharm is facing a double blow, a dispute among its major shareholders and the return of rights to a key pipeline asset, and has slipped into a valuation discount.While solid core profitability provides a cushion, further out-licensing of follow-up obesity drugs and a resolution of governance risk are expected to be the main turning points for a revaluation.Inheritance Tax Sparked the Feud, Now a KRW 60 Billion LawsuitHanmi Pharmaceutical Group’s operating environment is clouded from every direction, industry sources said on Oct. 18. The governance risk began after the death of founder L
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[그래픽 뉴스] ‘순대’가 경제용어라고? 순(純)대외자산, 한국의 진짜 해외자산은 얼마일까?
[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?
[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'
환전·로또·육아휴직까지 하반기부터 달라지는 제도 TOP11
[그래픽 뉴스] 은퇴후 30년 부모님 세대의 생존전략

FT도서

더보기